8-K: Eli Lilly Q1 2026 Results: Strong Growth, Raised Guidance

Eli Lilly reported a 56% revenue increase in Q1 2026, driven by strong volume growth, and raised its full-year financial guidance.

Summary

• Eli Lilly and Company announced strong financial results for the first quarter of 2026, with revenue soaring by 56% to $19.8 billion compared to the same period in 2025.
• Earnings per share (EPS) saw a significant increase, rising 170% to $8.26 on a reported basis and 156% to $8.55 on a non-GAAP basis.
• The company raised its full-year 2026 revenue guidance to a range of $82.0 billion to $85.0 billion and its non-GAAP EPS guidance to $35.50 to $37.00.
• Key product revenue, including Mounjaro and Zepbound, grew substantially, contributing to the overall revenue increase.
• Regulatory milestones included the U.S. FDA approval of Foundayo (orforglipron) for obesity.
• Pipeline advancements were noted across multiple therapeutic areas, including positive Phase 3 results for Foundayo in type 2 diabetes and obesity, and for Jaypirca in CLL/SLL.
• The company also announced several strategic business development agreements, including plans to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive filing, with strong financial performance, raised guidance, and significant pipeline and regulatory advancements.

Positives

• Revenue increased by 56% to $19.8 billion in Q1 2026, driven by a 65% increase in volume.
• Reported EPS increased by 170% to $8.26, and non-GAAP EPS increased by 156% to $8.55.
• Full-year 2026 revenue guidance was raised to $82.0 billion - $85.0 billion.
• Full-year 2026 non-GAAP EPS guidance was raised to $35.50 - $37.00.
• Mounjaro revenue increased by 125% to $8.7 billion.
• Zepbound revenue increased by 80% to $4.16 billion.
• U.S. revenue increased by 43% to $12.1 billion.
• International revenue increased by 81% to $7.7 billion.

Negatives

• Realized prices decreased by 13% overall, primarily due to lower prices for Mounjaro and Zepbound.
• Gross margin as a percent of revenue decreased by 0.6 percentage points to 81.9% on a reported basis, driven by lower realized prices.
• Acquired in-process research and development (IPR&D) charges were $584 million in Q1 2026, compared to $1.6 billion in Q1 2025, indicating a significant decrease in such charges year-over-year.

Risks

• Intense competition affecting the company's products, pipeline, or industry.
• Continued pricing pressures and the impact of governmental and private actors affecting pricing, reimbursement, and patient access to pharmaceuticals.
• Uncertainty and risks related to acquisitions and business development transactions.
• Potential issues with product supply, regulatory approvals, or negative outcomes stemming from manufacturing difficulties, disruptions, or shortages.
• Reliance on third-party relationships and outsourcing arrangements.
• Risks associated with the use of artificial intelligence or other emerging technologies.
• Global macroeconomic conditions, including uneven economic growth or downturns, trade disputes, and international tensions.
• Fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation.

Future Outlook

The company raised its full-year 2026 revenue guidance to a range of $82.0 billion to $85.0 billion and its non-GAAP EPS guidance to $35.50 to $37.00. Guidance does not include acquired in-process research and development (IPR&D) incurred after March 31, 2026.

Management Comments

• "2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion."
• "A key milestone was the U.S. FDA approval of Foundayo the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s."
• "We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions."

Industry Context

StockSavvy.ai notes that Eli Lilly's strong Q1 2026 performance, particularly the significant revenue growth driven by key products like Mounjaro and Zepbound, and the raised full-year guidance, positions it favorably within the highly competitive pharmaceutical sector, especially in the rapidly expanding obesity and diabetes markets.

Comparison to Industry Standards

• Eli Lilly's Q1 2026 revenue growth of 56% significantly outpaces the typical revenue growth rates seen in the broader pharmaceutical industry, which often range from single digits to low double digits.
• The reported EPS increase of 170% is exceptionally high and suggests strong operational leverage or significant one-time factors, far exceeding industry norms for quarterly EPS growth.
• The company's raised full-year revenue guidance of $82.0 billion to $85.0 billion places it among the top-tier global pharmaceutical companies by revenue, competing with giants like Pfizer, Roche, and Merck.
• The FDA approval of Foundayo (orforglipron) as an oral GLP-1 pill addresses a key unmet need for convenient weight management, a segment where competitors are also investing heavily, such as Novo Nordisk with its oral semaglutide (Rybelsus) and Wegovy.
• The strategic acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics demonstrate an aggressive approach to pipeline expansion and technology acquisition, mirroring strategies employed by other leading biopharmaceutical firms seeking to bolster their portfolios in areas like cell therapy and novel drug modalities.

Legal Proceedings

• Asset impairment, restructuring and other special charges of $279 million in Q1 2026 were primarily related to litigation matters.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial results, raised guidance, and potential for increased stock value.
• Employees: Potential for increased bonuses or incentives tied to company performance; continued investment in R&D may lead to new opportunities.
• Customers (Patients): Increased access to new medicines like Foundayo (orforglipron) and continued availability of key treatments like Mounjaro and Zepbound.
• Suppliers: Increased demand for products may lead to greater business volume for suppliers of raw materials and manufacturing services.
• Creditors: Improved financial health of the company strengthens its ability to meet debt obligations.

Next Steps

• Continue to invest in the company's early and late-stage portfolio.
• Execute on promotional efforts supporting ongoing and planned launches.
• Integrate acquired companies (Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics).
• Participate in the Investment Community Meeting on December 7, 2026.

Key Dates

Recommendation

The filing demonstrates exceptional Q1 2026 performance with a 56% revenue increase and significant EPS growth, coupled with a substantial raise in full-year guidance. Key product momentum, regulatory approvals (Foundayo), and strategic acquisitions indicate strong future growth prospects, justifying a strong buy recommendation.

Keywords

Eli Lilly, LLY, Q1 2026 Earnings, Financial Results, Revenue Growth, EPS, Mounjaro, Zepbound